[92] Later that week, Apotex's generic semaglutide ( Apo-Semaglutide ) was also approved as an injectable drug
Gallbladder disease, including gallstones (cholelithiasis) and gallbladder inflammation (cholecystitis), has been reported with GLP-1 receptor agonists as a class
[DOI] [PMC free article] [PubMed] [Google Scholar] 190.Raja-Khan N., Agito K., Shah J., Stetter C.M., Gustafson T.S., Socolow S., Kunselman A.R., Reibel D.K., Legro R.S
Even so, he said, combined with a planned $50 monthly Medicare copay for some GLP-1s that would cover many but not all Medicare beneficiaries with obesity, and possible Medicaid coverage, the deal "is a great step in the right direction to allow patients to get the care they need." Medicare, a federal program for people 65 and over and younger people with certain disabilities, currently does not cover GLP-1s for weight loss, nor does Medicaid in most states, including New York